← The record

Poly-L-Lactic Acid

Recommended Infectious diseaseAuthority RequiredNot applicable line 💬 consumer voice

Treatment of severe facial lipoatrophy caused by antiretroviral therapy in HIV-positive patients.

3
Submissions
2 resub
2008–09
On the record
$15k–75k
ICER range
3 sourced ICERs · 2008–2009
ICER stated
Cost basis

Decisions on record

2 decisions
  • Meeting Mar 2009 Recommended Injectable polymer to restore lost facial volume
  • Meeting Nov 2008 Not recommended Injectable polymer to restore lost facial volume

Access path

3 submissions · public record
  1. Nov 2008
    Recommended

    vs placebo

  2. Mar 2009
    Recommended · restricted

    ICER rose $45,000 → $75,000 (+67%)

  3. Mar 2009
    Recommended · restricted

    ICER rose $45,000 → $75,000 (+67%)

  4. PBS listing · Authority Required
RecommendedDeferredNot recommended

Cost-effectiveness

3 sourced ICERs · 2008–2009

Base case range; multivariate sensitivity analyses indicated the ICER could be in the $45,000–$75,000 range per QALY

Multivariate sensitivity analyses conducted during the evaluation indicated that the incremental cost effectiveness ratio could be in the $45,000 - $75,000 range per extra Quality Adjusted Life Year (QALY) gained from a base case of between $15,000 - $45,000/QALY. PBAC · 2009
ICER uncertainEconomic model disputed

Decision context

PopulationHIV-positive patients with severe facial lipoatrophy caused by antiretroviral therapy requiring facial administration.

Submission history

3 entries
DecidedOutcomeComparatorICEREvidence
Mar 2009 Recommended · restricted placebo $15k–75k RCT · QoL, Social Functioning, Mental Health Component, Anxiety, Depression
Mar 2009 Recommended · restricted placebo $15k–45k RCT
Nov 2008 Recommended placebo $15k–45k RCT · QoL

Consumer voice

Mar 2009

Consumer comments highlighted the social and psychological impact of facial lipoatrophy resulting from HIV treatment, and the significant effect on quality of life for people with this condition.

The PBAC noted the social and psychological impact that results from facial lipoatrophy which was highlighted in the submission and in the consumer comments and also the impact that facial lipoatrophy has on the quality of life of people with this condition as a result of their treatment for HIV. Consumer comments · PSD
quality of lifepsychological impactsocial impacttreatment burden

Similar precedents

By decision profile